JP5339566B2 - 真核生物細胞を改変する方法 - Google Patents

真核生物細胞を改変する方法 Download PDF

Info

Publication number
JP5339566B2
JP5339566B2 JP2002539535A JP2002539535A JP5339566B2 JP 5339566 B2 JP5339566 B2 JP 5339566B2 JP 2002539535 A JP2002539535 A JP 2002539535A JP 2002539535 A JP2002539535 A JP 2002539535A JP 5339566 B2 JP5339566 B2 JP 5339566B2
Authority
JP
Japan
Prior art keywords
gene
chromosomal locus
ltvec
cells
endogenous gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002539535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536556A5 (https=
JP2004536556A (ja
Inventor
アリス エヌ． エコノマイズ，
アンドリュー ジェイ． マーフィー，
デイビッド エム． ヴァレンズエラ，
デイビッド フレンデウェイ，
ジョージ ディー． ヤンコポーロス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2004536556A publication Critical patent/JP2004536556A/ja
Publication of JP2004536556A5 publication Critical patent/JP2004536556A5/ja
Application granted granted Critical
Publication of JP5339566B2 publication Critical patent/JP5339566B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2002539535A 2000-10-31 2001-10-31 真核生物細胞を改変する方法 Expired - Lifetime JP5339566B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24466500P 2000-10-31 2000-10-31
US60/244,665 2000-10-31
US09/732,234 US6586251B2 (en) 2000-10-31 2000-12-07 Methods of modifying eukaryotic cells
US09/732,234 2000-12-07
PCT/US2001/045375 WO2002036789A2 (en) 2000-10-31 2001-10-31 Methods of modifying eukaryotic cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010136321A Division JP2010220628A (ja) 2000-10-31 2010-06-15 真核生物細胞を改変する方法
JP2013108631A Division JP5892975B2 (ja) 2000-10-31 2013-05-23 真核生物細胞を改変する方法

Publications (3)

Publication Number Publication Date
JP2004536556A JP2004536556A (ja) 2004-12-09
JP2004536556A5 JP2004536556A5 (https=) 2005-04-07
JP5339566B2 true JP5339566B2 (ja) 2013-11-13

Family

ID=26936709

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2002539535A Expired - Lifetime JP5339566B2 (ja) 2000-10-31 2001-10-31 真核生物細胞を改変する方法
JP2010136321A Pending JP2010220628A (ja) 2000-10-31 2010-06-15 真核生物細胞を改変する方法
JP2013108631A Expired - Lifetime JP5892975B2 (ja) 2000-10-31 2013-05-23 真核生物細胞を改変する方法
JP2013247817A Expired - Lifetime JP5945263B2 (ja) 2000-10-31 2013-11-29 真核生物細胞を改変する方法
JP2014265082A Withdrawn JP2015062432A (ja) 2000-10-31 2014-12-26 真核生物細胞を改変する方法
JP2017024803A Expired - Lifetime JP6486979B2 (ja) 2000-10-31 2017-02-14 真核生物細胞を改変する方法
JP2017024802A Withdrawn JP2017123855A (ja) 2000-10-31 2017-02-14 真核生物細胞を改変する方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2010136321A Pending JP2010220628A (ja) 2000-10-31 2010-06-15 真核生物細胞を改変する方法
JP2013108631A Expired - Lifetime JP5892975B2 (ja) 2000-10-31 2013-05-23 真核生物細胞を改変する方法
JP2013247817A Expired - Lifetime JP5945263B2 (ja) 2000-10-31 2013-11-29 真核生物細胞を改変する方法
JP2014265082A Withdrawn JP2015062432A (ja) 2000-10-31 2014-12-26 真核生物細胞を改変する方法
JP2017024803A Expired - Lifetime JP6486979B2 (ja) 2000-10-31 2017-02-14 真核生物細胞を改変する方法
JP2017024802A Withdrawn JP2017123855A (ja) 2000-10-31 2017-02-14 真核生物細胞を改変する方法

Country Status (18)

Country Link
US (1) US6586251B2 (https=)
EP (1) EP1399575B1 (https=)
JP (7) JP5339566B2 (https=)
KR (1) KR100833136B1 (https=)
CN (1) CN100497642C (https=)
AT (1) ATE332388T1 (https=)
AU (2) AU2004802A (https=)
BR (1) BRPI0115096B1 (https=)
CA (1) CA2426398C (https=)
CZ (1) CZ304856B6 (https=)
DE (1) DE60121372T2 (https=)
HU (1) HU227639B1 (https=)
MX (1) MXPA03003797A (https=)
NO (1) NO332300B1 (https=)
NZ (1) NZ525511A (https=)
PL (1) PL204759B1 (https=)
RU (1) RU2290441C2 (https=)
WO (1) WO2002036789A2 (https=)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908744B1 (en) * 2000-03-14 2005-06-21 Regeneron Pharmaceuticals, Inc. Methods of stimulating cartilage formation
WO2002014495A2 (en) * 2000-08-14 2002-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced homologous recombination mediated by lambda recombination proteins
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
WO2004098490A2 (en) 2002-05-17 2004-11-18 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CA2496233A1 (en) * 2002-09-09 2004-03-18 California Institute Of Technology Methods and compositions for the generation of humanized mice
WO2004067725A2 (en) * 2003-01-30 2004-08-12 Regeneron Pharmaceuticals, Inc. Methods of identifying modulators of nmur2-mediated activity
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US20060117396A1 (en) * 2004-11-30 2006-06-01 Murphy Andrew J Assay methods for identifying modulators of OPSDL3 and transgenic knockouts
PT2125894T (pt) 2007-03-22 2019-02-27 Biogen Ma Inc Proteínas de ligação incluindo anticorpos, derivados de anticorpos e fragmentos de anticorpos que se ligam especificamente ao cd154 e as suas utilizações
DK2602323T3 (en) 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
CA2708776A1 (en) * 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
EP2281050B1 (en) * 2008-04-14 2014-04-02 Sangamo BioSciences, Inc. Linear donor constructs for targeted integration
US20090328240A1 (en) * 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
DE102008002715A1 (de) * 2008-06-27 2009-12-31 Evonik Röhm Gmbh 2-Hydroxyisobuttersäure produzierende rekombinante Zelle
EP2346994B1 (en) 2008-09-30 2022-02-16 Ablexis, LLC Knock-in mice for the production of chimeric antibodies
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
PT2485583T (pt) 2009-10-06 2016-09-22 Univ Yale Ratinhos geneticamente modificados e enxerto
EP2494047B1 (en) 2009-10-29 2017-01-04 Regeneron Pharmaceuticals, Inc. Multifunctional alleles
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
PL3498730T3 (pl) 2009-12-21 2026-04-07 Regeneron Pharmaceuticals, Inc. Humanizowane myszy fc gamma r
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SI2501817T2 (sl) * 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
KR102203727B1 (ko) 2010-03-31 2021-01-18 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9012717B2 (en) 2010-06-22 2015-04-21 Regeneron Pharmaceuticals, Inc. Human lambda light chain mice
JP6482757B2 (ja) 2010-07-26 2019-03-13 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． トランスジェニック動物および使用方法
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
MX350385B (es) 2011-02-15 2017-09-04 Regeneron Pharma Ratones de m-csf humanizada.
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
PL2631654T3 (pl) 2011-05-12 2015-09-30 Regeneron Pharma Oznaczenie uwalniania neuropeptydu dla kanałów sodowych
RS59728B1 (sr) 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
LT3424947T (lt) 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
SI2770821T1 (en) 2011-10-28 2018-01-31 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex of mice
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
DK3590332T3 (da) 2011-10-28 2022-05-23 Regeneron Pharma Genmodificerede mus, der eksprimerer kimære major histokompatibilitetskompleks (MHC) II-molekyler
EP2773323A4 (en) 2011-10-31 2015-04-22 Merck Sharp & Dohme NANO-SUSPENSION METHOD
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
RU2664181C2 (ru) 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
RS62023B1 (sr) 2012-02-01 2021-07-30 Regeneron Pharma Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene
IN2014DN08163A (https=) 2012-03-06 2015-05-01 Regeneron Pharma
MX2014011047A (es) 2012-03-16 2015-04-08 Regeneron Pharma Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
KR102228296B1 (ko) 2012-03-16 2021-03-17 리제너론 파마슈티칼스 인코포레이티드 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
SG10201700360VA (en) 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
IN2014DN09261A (https=) 2012-04-25 2015-07-10 Regeneron Pharma
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
AR091482A1 (es) * 2012-06-21 2015-02-04 Recombinetics Inc Celulas modificadas geneticamente y metodos par su obtencion
EP3494996B1 (en) 2012-08-23 2026-04-15 Agensys, Inc. Antibody drug conjugates (adc) that bind to 158p1d7 proteins
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
UA118090C2 (uk) * 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
IN2015DN02032A (https=) 2012-09-07 2015-08-14 Univ Yale
CA2887706C (en) 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
KR102714111B1 (ko) 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
PL2958937T3 (pl) 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej
JP6456351B2 (ja) 2013-03-11 2019-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ主要組織適合複合体（ｍｈｃ）クラスｉ分子を発現する遺伝子導入マウス
CA3249218A1 (en) 2013-03-11 2026-03-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
CN105189545A (zh) 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
WO2014160202A1 (en) 2013-03-13 2014-10-02 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
JP6510518B2 (ja) 2013-08-01 2019-05-08 アジェンシス，インコーポレイテッド Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ）
IL294443A (en) 2013-08-07 2022-09-01 Regeneron Pharma Lincrna-deficient non-human animals
MY191512A (en) 2013-09-18 2022-06-28 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
CN105592695B (zh) 2013-09-23 2018-04-10 瑞泽恩制药公司 具有人源化信号调节蛋白基因的非人动物
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
SG10201811701YA (en) 2013-11-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized a proliferation-inducing ligand gene
CA2929846C (en) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
US9546384B2 (en) * 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
SMT201800653T1 (it) 2013-12-11 2019-01-11 Regeneron Pharma Metodi e composizioni per la modificazione indirizzata a bersaglio di un genoma
WO2015108102A1 (ja) 2014-01-15 2015-07-23 国立大学法人 群馬大学 Ａｔｐ可視化動物およびその用途
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
SG10202002187WA (en) 2014-05-19 2020-04-29 Regeneron Pharma Genetically modified non-human animals expressing human epo
US9497945B2 (en) 2014-05-30 2016-11-22 Regeneron Pharmaceuticals, Inc. Humanized dipeptidyl peptidase IV (DPP4) animals
RS60359B1 (sr) 2014-06-06 2020-07-31 Regeneron Pharma Postupci i kompozicije za modifikovanje ciljanog lokusa
ES2783424T3 (es) 2014-06-19 2020-09-17 Regeneron Pharma Animales no humanos que tienen un gen de muerte celular programada 1 humanizado
HUE049405T2 (hu) 2014-06-23 2020-09-28 Regeneron Pharma Nukleáz-közvetített DNS-összeállítás
KR102386101B1 (ko) 2014-06-26 2022-04-14 리제너론 파마슈티칼스 인코포레이티드 표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
CA2959428A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
DK3207124T3 (da) 2014-10-15 2019-08-12 Regeneron Pharma Fremgangsmåder og sammensætninger til generering eller bevaring af pluripotente celler
ES2731437T3 (es) * 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
RU2020122439A (ru) 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
SI3086637T1 (sl) 2014-12-05 2019-04-30 Regeneron Pharmaceuticals, Inc. Nehumane živali s humaniziranim označevalcem diferenciacije gena CD47
HUE052606T2 (hu) 2014-12-09 2021-05-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
KR102530821B1 (ko) 2014-12-19 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물
ES2884844T3 (es) 2015-03-09 2021-12-13 Agensys Inc Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
IL274285B (en) 2015-03-16 2022-07-01 Regeneron Pharma Non-human animals exhibiting reduced upper and lower motor neuron function and sensory perception
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CN113349159B (zh) 2015-04-06 2022-11-11 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
KR102658190B1 (ko) 2015-04-13 2024-04-17 리제너론 파마슈티칼스 인코포레이티드 인간화된 sirpa-il15 녹인 마우스 및 이의 이용 방법
WO2016187356A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
JP6619822B2 (ja) 2015-05-29 2019-12-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｃ９ｏｒｆ７２遺伝子座における破壊を有する非ヒト動物
US10412939B2 (en) 2015-09-02 2019-09-17 Regeneron Pharmaceuticals, Inc. Rodent model of prostate cancer
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
SG11201803409UA (en) 2015-11-20 2018-05-30 Regeneron Pharma Non-human animals having a humanized lymphocyte-activation gene 3
JP7110096B2 (ja) * 2015-11-24 2022-08-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド レトロウイルス産生のための一時的トランスフェクション法
EP3380604B1 (en) * 2015-11-24 2022-12-28 GlaxoSmithKline Intellectual Property Development Limited Stable cell lines for retroviral production
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
AU2017206785C1 (en) 2016-01-13 2023-09-07 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
US20170218398A1 (en) * 2016-01-30 2017-08-03 Markus Alexander Brown Method to selectively target cancerous cells for genetic manipulation
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
MX2018009513A (es) * 2016-02-04 2019-01-31 Regeneron Pharma Animales no humanos que tienen un gen angptl8 modificado genéticamente.
CA3014292A1 (en) 2016-02-12 2017-08-17 Regeneron Pharmaceuticals, Inc. Methods and systems for detection of abnormal karyotypes
AU2017221425A1 (en) 2016-02-16 2018-08-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
US20170286594A1 (en) 2016-03-29 2017-10-05 Regeneron Pharmaceuticals, Inc. Genetic Variant-Phenotype Analysis System And Methods Of Use
IL323024A (en) 2016-05-20 2025-10-01 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide RNAs
HUE061619T2 (hu) 2016-06-03 2023-07-28 Regeneron Pharma Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
EP3476865B1 (en) 2016-06-28 2023-09-13 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Method for constructing pd-1 gene-modified humanized animal model and use thereof
JP2019523009A (ja) 2016-07-29 2019-08-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｃ末端切断型フィブリリン−１の発現をもたらす変異を有するマウス
JP7026678B2 (ja) * 2016-09-30 2022-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ９ｏｒｆ７２座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物
WO2018128691A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
NZ755816A (en) 2017-01-19 2026-03-27 Omniab Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
AU2018224227A1 (en) 2017-02-27 2019-08-29 Regeneron Pharmaceuticals, Inc. Non-human animal models of Retinoschisis
CN111182790A (zh) 2017-07-31 2020-05-19 瑞泽恩制药公司 Crispr报告体非人类动物及其用途
WO2019028032A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF
MX394999B (es) 2017-09-29 2025-03-24 Regeneron Pharma Animales no humanos que comprenden un locus ttr humanizado y metodos de uso
PT3687287T (pt) 2017-09-29 2023-11-03 Regeneron Pharma Roedores que expressam complexo c1q humanizado
WO2019072241A1 (en) * 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
IL310006A (en) 2017-11-30 2024-03-01 Regeneron Pharma Non-human animals containing a humanized TRKB locus
DK4140297T3 (da) 2017-12-05 2025-06-23 Regeneron Pharma Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf
CN111885915B (zh) 2018-03-19 2023-04-28 瑞泽恩制药公司 使用crispr/cas系统对动物进行转录调制
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
DK3773713T3 (da) 2018-04-06 2025-08-18 Regeneron Pharma Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI
CN112639980A (zh) 2018-06-01 2021-04-09 瑞泽恩制药公司 用于基于稀疏向量的矩阵变换的方法和系统
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
IL278267B2 (en) 2018-07-16 2025-02-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
CN109504708A (zh) * 2018-12-03 2019-03-22 江苏集萃药康生物科技有限公司 一种筛选标记自我删除的基因打靶载体及方法
CA3120799A1 (en) 2018-12-20 2020-06-25 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
US20220104468A1 (en) 2019-01-22 2022-04-07 St. Jude Children's Research Hospital Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
JP2022520819A (ja) 2019-02-22 2022-04-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子改変ナトリウムチャネルを有する齧歯類およびその使用方法
WO2020206134A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods for scarless introduction of targeted modifications into targeting vectors
ES2966625T3 (es) 2019-04-04 2024-04-23 Regeneron Pharma Roedores que comprenden un locus del factor de coagulación 12 humanizado
WO2020214690A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
SG11202111258TA (en) 2019-06-05 2021-11-29 Regeneron Pharma Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
US11622547B2 (en) 2019-06-07 2023-04-11 Regeneran Pharmaceuticals, Inc. Genetically modified mouse that expresses human albumin
CA3217237A1 (en) 2019-06-27 2020-12-30 Regeneration Pharmaceuticals, Inc. Modeling tdp-43 proteinopathy
AU2020300002A1 (en) 2019-07-01 2022-02-24 Tonix Pharma Limited Anti-CD154 antibodies and uses thereof
WO2021066869A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
EP4096396A1 (en) 2020-01-28 2022-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
EP4099821A1 (en) 2020-02-07 2022-12-14 Regeneron Pharmaceuticals, Inc. <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
WO2021195079A1 (en) 2020-03-23 2021-09-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
WO2021216505A1 (en) 2020-04-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cxcl13 gene
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
RU2751237C1 (ru) * 2020-06-10 2021-07-12 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
KR20230024822A (ko) 2020-06-25 2023-02-21 주식회사 휴맵 이형접합성 형질전환 동물
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
AU2021352420A1 (en) 2020-10-01 2023-04-27 Regeneron Pharmaceuticals, Inc. Rodent animals expressing human cr1
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
KR20230124973A (ko) 2020-12-21 2023-08-28 리제너론 파마슈티칼스 인코포레이티드 인간화 tslp 유전자, 인간화 tslp 수용체 유전자, 및/또는인간화 il7ra 유전자를 갖는 비인간 동물
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
US20240059781A1 (en) 2021-01-06 2024-02-22 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
AU2022249328A1 (en) 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
US20240199725A1 (en) 2021-04-16 2024-06-20 Korea University Research And Business Foundation Human antibody targeting covid-19 virus
JP2024523290A (ja) 2021-06-18 2024-06-28 ナミ セラピューティクス， インコーポレイテッド がんの処置およびその方法における使用のための、マスクされたＩ型インターフェロン（ＩＦＮαおよびＩＦＮβ）を含む融合タンパク質組成物
EP4423271A2 (en) 2021-10-28 2024-09-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
CN118632622A (zh) 2021-12-08 2024-09-10 瑞泽恩制药公司 突变型肌纤蛋白疾病模型及其用途
WO2023122506A1 (en) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci
US20250194571A1 (en) 2022-02-07 2025-06-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
US20230257432A1 (en) 2022-02-11 2023-08-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for screening 4r tau targeting agents
EP4514125A1 (en) 2022-04-26 2025-03-05 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
WO2023235677A1 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Animal model of tdp-43 proteinopathy
US20230417899A1 (en) 2022-06-27 2023-12-28 Oshkosh Corporation Position tracking for a lift device
IL318159A (en) 2022-07-19 2025-03-01 Regeneron Pharma Genetically modified animal model and its use to model the human immune system
IL319406A (en) 2022-09-22 2025-05-01 Regeneron Pharma Genetically modified mice expressing components of the human cellular immune system
WO2024073679A1 (en) 2022-09-29 2024-04-04 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
WO2024163650A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Animals comprising a modified klhdc7b locus
EP4727971A1 (en) 2023-06-13 2026-04-22 Adcentrx Therapeutics Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
US20240415103A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025122669A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized complement factor b gene
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2025235388A1 (en) 2024-05-06 2025-11-13 Regeneron Pharmaceuticals, Inc. Transgene genomic identification by nuclease-mediated long read sequencing
WO2025250495A1 (en) 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
WO2025264533A1 (en) 2024-06-17 2025-12-26 Adcentrx Therapeutics Inc. Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026039661A1 (en) 2024-08-15 2026-02-19 Regeneron Pharmaceuticals, Inc. Non-human animals with humanized fc epsilon receptors that lack functional alpha-1, 3-galactosyltransferase (ggta1)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
NZ255101A (en) * 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
DE4228162C1 (de) * 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
US5436149A (en) 1993-02-19 1995-07-25 Barnes; Wayne M. Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension
CA2161351C (en) * 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
ATE307830T1 (de) * 1999-02-05 2005-11-15 Therapeutic Human Polyclonals Aus nicht-menschlichen transgenen tieren gewonnene menschliche polyklonale antikörper
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells

Also Published As

Publication number Publication date
US20020106628A1 (en) 2002-08-08
DE60121372T2 (de) 2007-07-26
JP2017123855A (ja) 2017-07-20
CN100497642C (zh) 2009-06-10
BRPI0115096B1 (pt) 2016-03-01
KR20030074614A (ko) 2003-09-19
JP5892975B2 (ja) 2016-03-23
EP1399575A2 (en) 2004-03-24
HUP0301575A2 (hu) 2003-09-29
CZ20031197A3 (cs) 2003-11-12
NO20031897D0 (no) 2003-04-28
NZ525511A (en) 2006-02-24
NO332300B1 (no) 2012-08-20
JP6486979B2 (ja) 2019-03-20
WO2002036789A3 (en) 2003-12-31
HU227639B1 (en) 2011-10-28
CN1484707A (zh) 2004-03-24
DE60121372D1 (de) 2006-08-17
CA2426398A1 (en) 2002-05-10
RU2290441C2 (ru) 2006-12-27
AU2004802A (en) 2002-05-15
PL361927A1 (en) 2004-10-04
JP2010220628A (ja) 2010-10-07
JP5945263B2 (ja) 2016-07-05
EP1399575B1 (en) 2006-07-05
NO20031897L (no) 2003-06-24
HK1059802A1 (en) 2004-07-16
JP2013162803A (ja) 2013-08-22
KR100833136B1 (ko) 2008-05-28
PL204759B1 (pl) 2010-02-26
US6586251B2 (en) 2003-07-01
BR0115096A (pt) 2003-10-07
HUP0301575A3 (en) 2010-01-28
WO2002036789A2 (en) 2002-05-10
MXPA03003797A (es) 2004-04-20
JP2004536556A (ja) 2004-12-09
RU2003116125A (ru) 2005-01-20
ATE332388T1 (de) 2006-07-15
CA2426398C (en) 2010-10-26
CZ304856B6 (cs) 2014-12-10
AU2002220048B2 (en) 2006-09-21
JP2017104125A (ja) 2017-06-15
JP2015062432A (ja) 2015-04-09
JP2014039567A (ja) 2014-03-06

Similar Documents

Publication Publication Date Title
JP6486979B2 (ja) 真核生物細胞を改変する方法
US10344299B2 (en) Compositions and methods for modifying cells
AU2002220048A1 (en) Methods of modifying eukaryotic cells
JP5692863B2 (ja) 真核生物細胞を改変する方法
HK1059802B (en) Methods of modifying eukaryotic cells
IL155580A (en) Ex vivo method for modifying endogenous gene or chromosomal locus in eukaryotic cells

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100628

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20101022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130805

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5339566

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term